ASKA Pharmaceutical Holdings
Basic Information
- Stock Code
- 4886
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- April 2021
- Listing Year
- April 2021
- Official Website
- https://www.aska-pharma-hd.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Japan Ritec, Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Mochida Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings, Nichi Enter
Overview
ASKA Pharmaceutical Holdings is a pharmaceutical holding company established in 2021 that integrates mid-sized domestic pharmaceutical companies to develop a stable pharmaceutical business.
Current Situation
ASKA Pharmaceutical Holdings recorded consolidated net sales of approximately 56.6 billion yen and ordinary income of approximately 4.8 billion yen in the fiscal year ending March 2022, making it a financially sound mid-sized pharmaceutical group. Its main business is the manufacture and sale of prescription pharmaceuticals, with strengths in gastrointestinal treatments and thyroid hormone preparations. Subsidiary ASKA Pharmaceutical also handles generic drug OEM and veterinary pharmaceuticals, maintaining a broad pharmaceutical business structure. Since its establishment as a holding company in 2021, it has been improving operational efficiency and strengthening its business foundation. It operates multiple R&D sites including the Kawasaki Research Institute and Fukushima Iwaki Plant. It emphasizes environmental and safety measures and has handled product recalls in the past. In the future, expectations include new drug development, overseas market expansion, and focus on biopharmaceuticals. Major shareholders include Japan Master Trust Bank. Amid intensifying competition in the pharmaceutical industry, it is strengthening stable earnings and management base while seeking growth.
Trivia
Interesting Facts
- Corporate group born from the merger of Grelan Pharmaceutical and Teikoku Soki Pharmaceutical
- Became a holding company in 2021 and newly listed on the Tokyo Stock Exchange Prime Market
- Also engages in veterinary pharmaceuticals business, focusing on pet medicine
- Has conducted recalls in the past due to carcinogenic substances mixed in raw materials
- Group widely conducts clinical testing and clinical trial support services
- Japan Master Trust Bank and Takeda Pharmaceutical are major shareholders
- Owns research institute in Kawasaki and manufacturing plant in Fukushima Iwaki
- Strength in OEM manufacturing of prescription pharmaceuticals
- Multiple sales offices deployed from Hokkaido to Kyushu
- Previously had capital ties with Zeria Pharmaceutical
Hidden Connections
- Mid-sized pharmaceutical company with capital ties to Takeda Pharmaceutical as a major shareholder
- Built transaction relationships with many small and medium pharmaceutical companies through generic drug OEM
- Supports new drug development of major pharmaceutical companies through clinical testing outsourcing
- Veterinary pharmaceuticals business provides products in collaboration with agriculture, forestry, and fisheries
- Established nationwide sales network through numerous regional sales offices
- Achieved reorganization and efficiency of the entire group through holding company transition
- High-quality management system in pharmaceutical manufacturing has obtained Ministry of Health, Labour and Welfare certification
- Rapid recall response is evaluated in the industry
Future Outlook
Growth Drivers
- Expansion of generic drug market and increasing demand
- Increased demand for prescription drugs due to domestic aging population
- Growth in medical devices and veterinary pharmaceuticals
- Technology investment in new drugs and biopharmaceuticals
- Diversification and expansion of clinical trial outsourcing business
- Stable demand through regionally focused sales expansion
- Improved research efficiency through digital technology utilization
- Enhanced brand trust through strengthened regulatory compliance
- Expansion of global market entry opportunities
- Social value creation based on sustainable management
Strategic Goals
- Enter top class in domestic generic drug OEM business
- 30% sales increase through new pharmaceutical development
- Start overseas expansion of clinical trial services
- Expand domestic market share in veterinary pharmaceuticals
- Achieve 50% reduction in plant environmental impact
- Complete digitization and efficiency of sales bases
- Promote innovation through diverse talent utilization
- Strengthen quality management system to zero product recalls
- Build sustainable supply chain
- Achieve group-wide sales over 100 billion yen
Business Segments
Pharmaceutical Manufacturing and OEM Contracting
- Overview
- Secures stable revenue through OEM contract manufacturing and API supply for other companies' pharmaceuticals.
- Competitiveness
- High-quality pharmaceutical manufacturing technology and flexible production capabilities
- Customers
-
- Pharmaceutical companies
- Biotech ventures
- Medical institutions
- Research institutions
- Products
-
- Generic drug OEM
- Pharmaceutical contract manufacturing
- API supply
- Packaging and logistics support
Clinical Testing and Trial Services
- Overview
- Provides essential clinical trials and testing outsourcing for new drug development.
- Competitiveness
- Diverse testing expertise and clinical trial management system
- Customers
-
- Pharmaceutical companies
- Medical institutions
- Testing organizations
- Products
-
- Clinical trial outsourcing
- Clinical trial support services
- Testing kit provision
Veterinary Pharmaceuticals and Feed Additives
- Overview
- Specialized division for manufacturing and selling pet and livestock pharmaceuticals.
- Competitiveness
- Manufacturing experience in animal pharmaceuticals and diverse product lineup
- Customers
-
- Veterinary clinics
- Livestock producers
- Pet-related companies
- Products
-
- Animal vaccines
- Feed additives
- Veterinary pharmaceuticals
Medical Device Sales and Support
- Overview
- Handles medical device sales and after-sales services for healthcare sites.
- Competitiveness
- Diverse product range tailored to medical site needs
- Customers
-
- Medical institutions
- Nursing homes
- Home care providers
- Products
-
- Medical device sales
- Maintenance services
- Medical information support
Quasi-Drugs and Health Foods
- Overview
- Product lineup of quasi-drugs tailored to health-conscious markets.
- Competitiveness
- Product development focused on quality and safety
- Customers
-
- Drugstores
- Specialty stores
- Hospital purchasing departments
- Products
-
- Skincare products
- Health supplements
- Beauty products
Competitive Advantage
Strengths
- Specialized manufacturing technology for prescription pharmaceuticals
- Diversified pharmaceutical business portfolio
- Stable management base and capital structure
- Abundant clinical trial outsourcing expertise
- Nationwide sales and distribution network
- Strong trust relationships with a wide range of medical institutions
- Efficient collaboration system among subsidiaries
- Excellent quality control system
- Rich lineup of veterinary pharmaceuticals
- Proven OEM contract manufacturing capabilities
- Thorough compliance with laws and safety management
- Highly specialized R&D facilities
Competitive Advantages
- Established position in the domestic mid-sized pharmaceutical market
- Diverse prescription product lineup
- Optimized management through holding company structure
- Strategic acceptance of generic drug OEM from other companies
- Composite expansion in medical devices and veterinary products
- Multifaceted provision of clinical trial services
- Capital support from stable major shareholders
- Regionally rooted sales organization
- Track record of rapid product recall response
- Technical and resource support system from parent company
- Acquisition of advanced quality management certifications for pharmaceutical manufacturing
- Established wide sales channels
Threats
- Price pressures from intensifying pharmaceutical industry competition
- Increasing new drug development costs and development risks
- Concerns over product approval delays due to stricter regulations
- Further acceleration of competition in generic drug market
- Barriers to overseas expansion and currency risks
- Cost increases from raw material price fluctuations
- Revenue decline risks from patent expirations
- Declining demand due to domestic population decline
- Supply chain disruption risks
- Potential brand damage from drug harm or quality issues
Innovations
2021: Organizational restructuring through holding company establishment
- Overview
- Established ASKA Pharmaceutical Holdings to promote group management efficiency.
- Impact
- Achieved optimal allocation of management resources and strengthened growth strategy
2022: Expansion of generic drug OEM production capacity
- Overview
- Newly established generic drug OEM manufacturing lines to strengthen production capacity.
- Impact
- Sales growth effect from increased orders
2023: Introduction of digital R&D system
- Overview
- Introduced the latest digital management system at research institutes to improve research efficiency.
- Impact
- Achieved shorter development periods and strengthened quality control
Sustainability
- Promotion of environmental load reduction measures at pharmaceutical plants
- Thorough provision of safe and high-quality products
- Active participation in regional medical support activities
- Proper treatment and reduction of pharmaceutical waste
- Employee health management and workplace environment improvement
- Regular compliance training
- Sustainable procurement supply chain management
- Promotion of environmentally friendly equipment introduction
- Corporate activities mindful of social responsibility
- Promotion of diversity and inclusion